Preimplantation Genetic Testing Market Anticipated to Grow at 8.8% CAGR Through 2032 - Persistence Market Research

The global Preimplantation Genetic Testing (PGT) market is witnessing strong momentum as the integration of advanced genomic technologies into fertility treatments reshapes reproductive medicine. Valued at US$552.7 million in 2025, the market is projected to grow at a CAGR of 8.8%, reaching US$999.2 million by 2032. This expansion is underpinned by rising infertility rates, delayed childbearing, and increasing awareness of hereditary genetic conditions. Preimplantation genetic testing, used in conjunction with in vitro fertilization (IVF), allows for screening embryos before implantation, ensuring that only genetically healthy embryos are selected-thereby improving pregnancy outcomes and reducing the risk of inherited diseases.

The leading market segment by technology is Next-Generation Sequencing (NGS), which has revolutionized genetic testing by offering high-throughput, accurate, and cost-effective analysis. NGS-based PGT-A (aneuploidy testing) has significantly enhanced the success rates of IVF procedures, particularly for women of advanced maternal age. Regionally, North America dominates the global PGT market, supported by robust healthcare infrastructure, high adoption of assisted reproductive technologies (ART), and favorable reimbursement frameworks. Meanwhile, the Asia Pacific region is emerging as the fastest-growing market, fueled by expanding fertility treatment centers, increasing awareness of genetic screening, and supportive government policies aimed at improving reproductive healthcare.

Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/34757

Key Highlights from the Report

• The global Preimplantation Genetic Testing market will reach US$999.2 million by 2032, growing at a CAGR of 8.8%.
• North America leads the global market, supported by advanced IVF infrastructure and strong investment in genetic research.
• Asia Pacific is the fastest-growing region, driven by growing awareness of infertility solutions and expanding access to fertility care.
• Next-Generation Sequencing (NGS) dominates the technology segment due to its accuracy and comprehensive genomic coverage.
• Rising maternal age and infertility rates are key drivers increasing demand for PGT.
• Integration of AI and personalized medicine presents major opportunities for innovation and market expansion.

Market Segmentation

The preimplantation genetic testing market is broadly segmented by product type, technology, and application, each reflecting distinct growth dynamics within reproductive genomics.

By Product Type:
Kits dominate the global PGT market due to their ability to simplify and streamline testing workflows in IVF laboratories. These ready-to-use kits contain pre-validated reagents and optimized protocols that minimize human error and standardize genetic testing across facilities. Their user-friendly design and compatibility with automated platforms make them particularly appealing to fertility clinics aiming for consistency and operational efficiency. The rising demand for accessible, cost-effective, and high-throughput diagnostic solutions further strengthens the kits' market position, especially in emerging economies where specialized expertise may be limited.

By Technology:
Next-Generation Sequencing (NGS) stands as the leading technology segment, offering high-resolution analysis of chromosomal abnormalities and single-gene mutations. NGS enables simultaneous screening of multiple embryos, reducing the likelihood of implantation failure and miscarriage. Its precision and scalability have made it a preferred choice over traditional methods like fluorescence in situ hybridization (FISH) and array comparative genomic hybridization (aCGH). With falling sequencing costs and shorter turnaround times, NGS continues to drive technological progress and clinical adoption across IVF centers globally.

By Application:
Within applications, aneuploidy testing (PGT-A) holds a commanding share, accounting for approximately 41% of total market revenue in 2024. The high prevalence of chromosomal abnormalities-particularly among women over 35-drives this segment's dominance. PGT-A enhances embryo selection by identifying embryos with the correct number of chromosomes, which significantly improves IVF success rates. Other key applications include PGT-M (for monogenic/single-gene defects) and PGT-SR (for structural rearrangements), which cater to couples with known genetic risks, further expanding the scope of PGT in clinical settings.

Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/preimplantation-genetic-testing-market.asp

Regional Insights
North America

North America remains the largest regional market for preimplantation genetic testing, led by the United States. The region benefits from a combination of technological leadership, advanced healthcare systems, and widespread use of assisted reproductive technologies. A growing number of fertility clinics and IVF centers have incorporated PGT into standard reproductive care, supported by favorable insurance policies and regulatory oversight. The rising average maternal age and increasing awareness of genetic health have further amplified demand. Collaboration between biotechnology firms, academic institutions, and clinical laboratories continues to foster innovation, driving North America's leadership in both the research and commercial domains of PGT.

Europe

Europe follows closely, marked by steady growth in IVF adoption and expanding genetic screening programs. Countries like the UK, Germany, and France are leading adopters due to their robust fertility treatment infrastructure and proactive healthcare regulations. The UK, in particular, is expected to register the fastest growth between 2025 and 2032, supported by government funding for infertility treatments and growing patient awareness. The presence of major diagnostic companies, coupled with ongoing advancements in NGS and chromosomal screening, has created a well-established ecosystem for genetic testing in reproductive medicine.

Asia Pacific

The Asia Pacific region is emerging as a high-growth frontier for the PGT market. Rapid urbanization, improving healthcare accessibility, and increasing government support for fertility treatments are accelerating adoption. Countries such as China, India, and Japan are investing heavily in genomic research and IVF infrastructure. Rising infertility rates-driven by changing lifestyles, pollution, and delayed parenthood-have made assisted reproductive technologies more relevant than ever. The growing number of local diagnostic firms offering cost-effective testing solutions is also enhancing affordability and market penetration, positioning Asia Pacific as the fastest-growing region globally.

Market Drivers

One of the primary drivers of the global preimplantation genetic testing market is the increasing maternal age and rising infertility rates. Modern societal and professional trends have led many women to postpone childbearing, resulting in age-related fertility challenges. As fertility declines with age-dropping from roughly 20% per cycle in women in their early 30s to less than 5% after 40-couples increasingly turn to assisted reproductive technologies. PGT enhances IVF success rates by ensuring only genetically normal embryos are transferred, reducing miscarriage risks and improving live birth outcomes.

Additionally, the rising prevalence of genetic disorders such as cystic fibrosis, sickle cell anemia, and Down syndrome has heightened awareness of the importance of genetic screening. Technological innovations like NGS and AI-driven embryo selection are further transforming PGT accuracy and accessibility. The expansion of fertility clinics and supportive health policies in developed regions continue to amplify global demand for PGT as a standard step in modern reproductive care.

Market Restraints

Despite strong growth prospects, the PGT market faces several restraints that hinder widespread adoption. Clinical risks associated with embryo biopsy remain a major concern. The cell extraction process, though minimally invasive, can occasionally affect embryo viability or contribute to complications such as preeclampsia and preterm birth. Diagnostic inaccuracies and mosaicism-where embryos contain both normal and abnormal cells-can lead to false results, causing viable embryos to be discarded unnecessarily. A 2019 study indicated that nearly half of embryos classified as abnormal later resulted in healthy live births, highlighting the limitations of current testing methodologies.

Ethical and legal concerns also pose challenges. The potential misuse of genetic testing for non-medical reasons, such as sex selection, has led to stringent regulations in several countries. The 2024 Monash IVF case in Australia, involving misclassified embryos and a $56 million settlement, underscores the importance of accuracy and regulatory compliance. These factors, combined with the high cost of testing and limited insurance coverage in developing nations, continue to restrict PGT's broader market penetration.

Market Opportunities

The future of the preimplantation genetic testing market lies in technological convergence and precision medicine. Advances in Next-Generation Sequencing (NGS), artificial intelligence (AI), and non-invasive testing methods are paving the way for safer, faster, and more accurate embryo screening. AI-based algorithms, such as convolutional neural networks (CNNs) and predictive embryo assessment models, are being used to analyze digital images and genetic data, enhancing embryo viability predictions without invasive sampling.

Moreover, non-invasive PGT (niPGT), which uses cell-free DNA from spent embryo culture media, represents a promising frontier that minimizes embryo manipulation while maintaining diagnostic accuracy. The integration of these innovations with personalized reproductive medicine could significantly improve IVF outcomes, reduce costs, and expand accessibility. Partnerships between technology developers and fertility centers are expected to catalyze commercial adoption, especially in emerging markets.

Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/34757

Company Insights

The competitive landscape of the preimplantation genetic testing market is characterized by the presence of established global players and emerging biotechnology innovators. Companies are focusing on product innovation, strategic collaborations, and regional expansion to strengthen their market position.

Key Players Operating in the Market:
• Thermo Fisher Scientific, Inc.
• Cooper Surgical, Inc.
• Illumina, Inc.
• Abbott
• Agilent Technologies, Inc.
• Medicover Genetics
• Revvity Inc.
• Takara Bio Inc.
• Genea BIOMEDX
• SeraCare Life Sciences
• Shiva Scientific Company
• Others

Market Segmentation

By Product

Kits
Reagents and Consumables

By Technology

Next-Generation Sequencing
Fluorescence In Situ Hybridization
Polymerase Chain Reaction
Single-Nucleotide Polymorphism
Comparative Genomic Hybridization

By Application

Aneuploidy
X-Linked Disorders
Structural Chromosomal Abnormalities
Single Gene Disorders
Gender Identification
HLA Typing for Stem Cell Transplants

By Distribution Channel

Hospitals
Fertility Clinics
Diagnostic Laboratories
Academic & Research Institutions
Others

By Region

North America
Europe
East Asia
South Asia and Oceania
Latin America
Middle East and Africa

Recent Developments:

In February 2025, Thermo Fisher Scientific Inc. acquired Solventum's Purification & Filtration business for approximately US$4.1 billion, enhancing its capabilities in life sciences and genetic testing solutions.

In January 2025, Illumina, Inc. launched significant upgrades to its NovaSeq X Series, including a single-flow-cell system and advanced reagent kits, further reinforcing its leadership in high-throughput genomic sequencing.

Conclusion

The global Preimplantation Genetic Testing market stands at the intersection of technology, healthcare, and ethics-offering transformative potential for reproductive medicine. Driven by rising infertility rates, delayed parenthood, and advances in genomic analysis, the market is poised for robust growth through 2032. While ethical challenges, clinical risks, and regulatory complexities persist, ongoing innovations such as AI-enabled embryo analysis and non-invasive PGT promise to address these limitations.

As fertility clinics worldwide adopt precision medicine approaches, PGT is evolving from a niche diagnostic tool into an integral component of modern IVF practice. With North America maintaining technological leadership and Asia Pacific emerging as a high-growth hub, the market's future will be defined by innovation, accessibility, and ethical responsibility. In essence, the next decade will see preimplantation genetic testing transition from an advanced option to a standard of care-helping families worldwide achieve healthier, genetically sound pregnancies.

Read More Related Reports:

Human Papillomavirus (HPV) Testing Market https://www.persistencemarketresearch.com/market-research/human-papillomavirus-testing-market.asp
Combination Antibody Therapy Market https://www.persistencemarketresearch.com/market-research/combination-antibody-therapy-market.asp
Single-Use Bioprocess Systems Market https://www.persistencemarketresearch.com/market-research/single-use-bioprocess-system-market.asp
Allergic Rhinitis Market https://www.persistencemarketresearch.com/market-research/allergic-rhinitis-market.asp

Contact Us:

Persistence Market Research
Second Floor, 150 Fleet Street, London, EC4A 2DQ, United Kingdom
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.